Evaluation of Exenatide in Patients With Diabetic Neuropathy

NACompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Type 2 Diabetes MellitusDiabetic Peripheral Neuropathy
Interventions
DRUG

Exenatide

Exenatide is given according to current FDA prescribing guidelines. Exenatide and other diabetes medications will be titrated in order to achieve optimal blood glucose levels

DRUG

Glargine

Subjects will take 1 daily injection of insulin glargine in manner consistent with current prescribing guidelines. Glargine and other diabetes medications will be adjusted to achieve optimal levels of blood sugar control

Trial Locations (1)

48109

The University of Michigan Health System, Ann Arbor

Sponsors
All Listed Sponsors
collaborator

Amylin Pharmaceuticals, LLC.

INDUSTRY

collaborator

Eli Lilly and Company

INDUSTRY

lead

University of Michigan

OTHER

NCT00855439 - Evaluation of Exenatide in Patients With Diabetic Neuropathy | Biotech Hunter | Biotech Hunter